Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function. The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomize...
Saved in:
| Published in | Journal of the American College of Cardiology Vol. 73; no. 23; pp. 2961 - 2970 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
18.06.2019
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0735-1097 1558-3597 1558-3597 |
| DOI | 10.1016/j.jacc.2019.03.513 |
Cover
| Abstract | Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited.
The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function.
The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non–high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate.
There were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage ≥3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); pint = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (pint = 0.75)—preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage ≥3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were −2.5% (95% CI: -4.7% to -0.4%) for stage ≥3 CKD compared with −1.7% (95% CI: -2.8% to 0.5%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage.
LDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633)
[Display omitted] |
|---|---|
| AbstractList | Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited.BACKGROUNDData on PCSK9 inhibition in chronic kidney disease (CKD) is limited.The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function.OBJECTIVESThe purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function.The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non-high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate.METHODSThe FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non-high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate.There were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage ≥3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); pint = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (pint = 0.75)-preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage ≥3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were -2.5% (95% CI: -0.4% to -4.7%) for stage ≥3 CKD compared with -1.7% (95% CI: 0.5% to -2.8%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage.RESULTSThere were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage ≥3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); pint = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (pint = 0.75)-preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage ≥3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were -2.5% (95% CI: -0.4% to -4.7%) for stage ≥3 CKD compared with -1.7% (95% CI: 0.5% to -2.8%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage.LDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633).CONCLUSIONSLDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633). BACK GROUND Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. OBJECTIVES The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function. METHODS The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) amp;gt;= 70 mg/dl or non-high-density lipoprotein cholesterol amp;gt;= 100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate. RESULTS There were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with amp;gt;= stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage amp;gt;= 3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); p(int) = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (p(int) = 0.75)-preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage amp;gt;= 3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were -2.5% (95% CI: -0.4% to -4.7%) for stage amp;gt;= 3 CKD compared with -1.7% (95% CI: 0.5% to -2.8%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage. CONCLUSIONS LDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (C) 2019 by the American College of Cardiology Foundation. Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function. The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non–high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate. There were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage ≥3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); pint = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (pint = 0.75)—preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage ≥3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were −2.5% (95% CI: -4.7% to -0.4%) for stage ≥3 CKD compared with −1.7% (95% CI: -2.8% to 0.5%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage. LDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633) [Display omitted] BackgroundData on PCSK9 inhibition in chronic kidney disease (CKD) is limited.ObjectivesThe purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function.MethodsThe FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non–high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate.ResultsThere were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage ≥3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); pint = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (pint = 0.75)—preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage ≥3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were −2.5% (95% CI: -4.7% to -0.4%) for stage ≥3 CKD compared with −1.7% (95% CI: -2.8% to 0.5%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage.ConclusionsLDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633) Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function. The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non-high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate. There were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage ≥3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); p = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (p = 0.75)-preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage ≥3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were -2.5% (95% CI: -0.4% to -4.7%) for stage ≥3 CKD compared with -1.7% (95% CI: 0.5% to -2.8%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage. LDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633). AbstractBackgroundData on PCSK9 inhibition in chronic kidney disease (CKD) is limited. ObjectivesThe purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function. MethodsThe FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non–high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate. ResultsThere were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage ≥3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); p int = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (p int = 0.75)—preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage ≥3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were −2.5% (95% CI: -4.7% to -0.4%) for stage ≥3 CKD compared with −1.7% (95% CI: -2.8% to 0.5%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage. ConclusionsLDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk [FOURIER]; NCT01764633) |
| Author | Charytan, David M. Pineda, Armando Lira Sabatine, Marc S. Wasserman, Scott M. Olsson, Anders G. Giugliano, Robert P. Pedersen, Terje R. Im, KyungAh Sever, Peter S. Park, Jeong-Gun Keech, Anthony C. Deedwania, Prakash |
| Author_xml | – sequence: 1 givenname: David M. surname: Charytan fullname: Charytan, David M. email: david.charytan@nyulangone.org organization: Department of Medicine, NYU Langone Medical Center, New York, New York – sequence: 2 givenname: Marc S. surname: Sabatine fullname: Sabatine, Marc S. organization: Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts – sequence: 3 givenname: Terje R. surname: Pedersen fullname: Pedersen, Terje R. organization: Department of Medicine, Oslo University Hospital, Ullevål, Oslo, Norway – sequence: 4 givenname: KyungAh surname: Im fullname: Im, KyungAh organization: Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts – sequence: 5 givenname: Jeong-Gun surname: Park fullname: Park, Jeong-Gun organization: Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts – sequence: 6 givenname: Armando Lira surname: Pineda fullname: Pineda, Armando Lira organization: Amgen, Thousand Oaks, California – sequence: 7 givenname: Scott M. surname: Wasserman fullname: Wasserman, Scott M. organization: Amgen, Thousand Oaks, California – sequence: 8 givenname: Prakash surname: Deedwania fullname: Deedwania, Prakash organization: Cardiology Division, Veteran Affairs Central California Healthcare System, Fresno, California – sequence: 9 givenname: Anders G. surname: Olsson fullname: Olsson, Anders G. organization: University of California San Francisco School of Medicine, Fresno, California – sequence: 10 givenname: Peter S. surname: Sever fullname: Sever, Peter S. organization: Department of Medicine and Health Sciences, Linkӧping University, Linkӧping, Sweden – sequence: 11 givenname: Anthony C. surname: Keech fullname: Keech, Anthony C. organization: Department of Medicine, Imperial College London, London, United Kingdom – sequence: 12 givenname: Robert P. surname: Giugliano fullname: Giugliano, Robert P. organization: Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31196453$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-158544$$DView record from Swedish Publication Index |
| BookMark | eNqNks1O3DAUha2Kqgy0L9BFFambbjL1T5yJu6iEhqGgIiEN0O2V49jFU088tRNQ3oZn4cnqMHQWSEVdWF74O9f3nnMP0F7rW43Qe4KnBJPy82q6kkpNKSZiitmUE_YKTQjnVc64mO2hCZ4xnhMsZvvoIMYVxrisiHiD9hkhoiw4m6DlwhirpBoy2TbZpTS6GzJvssWtd171a1lntn24n98E31qVfbdNq4fs2EYto05PWXejs5OL6-XZYvlwfxWsdG_RayNd1O-e7kN0fbK4mp_m5xffzuZH57niFe_y2pDCpN5LXFCjtTRSCEF4ySlu0qGiYLqqBBc1NYY3dYkpFkZiQTlvCKHsELFt3b7dyOFOOgebYNcyDEAwjA7BCkaHYHQIMIPkUFLlW1W805u-3km8tHBsfxyBDz_B2R5I6rIoEv9py2-C_93r2MHaRqWdk632fQTKCowLJsSIfnyGrnwf2uQBUMpmVUrikfrwRPX1Wje7Bv5mkoBqC6jgYwzagLKd7KxvuyCte3k4-kz6X4583Yp0CuvW6gDK2RS2dL_0oONuBgKRAobLcavGpSKCFQKzcaIv_y4Ajbcv_f4HkTrZNQ |
| CitedBy_id | crossref_primary_10_1007_s12181_024_00716_6 crossref_primary_10_1007_s00059_022_05112_y crossref_primary_10_1016_j_jstrokecerebrovasdis_2021_105679 crossref_primary_10_1016_j_pcad_2024_12_004 crossref_primary_10_1016_j_nefroe_2022_07_003 crossref_primary_10_3389_fimmu_2021_796383 crossref_primary_10_31083_j_rcm2311380 crossref_primary_10_1007_s42399_022_01242_w crossref_primary_10_1097_MOL_0000000000000625 crossref_primary_10_3389_fphys_2020_595819 crossref_primary_10_1093_eurheartj_ehaa1050 crossref_primary_10_1016_j_amjmed_2023_06_013 crossref_primary_10_1007_s00059_020_05012_z crossref_primary_10_1016_j_mayocp_2024_03_025 crossref_primary_10_1681_ASN_2020091376 crossref_primary_10_1093_ehjcvp_pvae058 crossref_primary_10_31083_j_rcm2306188 crossref_primary_10_4093_dmj_2023_0067 crossref_primary_10_1007_s40265_025_02158_0 crossref_primary_10_1016_j_pharmthera_2019_107459 crossref_primary_10_1016_j_iccl_2020_03_002 crossref_primary_10_1016_j_atherosclerosis_2022_01_015 crossref_primary_10_1093_eurheartj_ehaa550 crossref_primary_10_1093_eurheartj_ehab484 crossref_primary_10_3389_fphys_2020_598649 crossref_primary_10_1016_j_acvd_2024_08_001 crossref_primary_10_1097_CRD_0000000000000441 crossref_primary_10_1186_s12882_023_03337_5 crossref_primary_10_3389_fendo_2024_1335489 crossref_primary_10_36290_vnl_2021_054 crossref_primary_10_1038_s41401_021_00660_1 crossref_primary_10_1096_fj_202300342RRR crossref_primary_10_4103_heartviews_heartviews_102_22 crossref_primary_10_7759_cureus_29140 crossref_primary_10_1016_j_iccl_2023_06_006 crossref_primary_10_1016_j_recesp_2021_10_016 crossref_primary_10_1016_j_jacc_2022_07_006 crossref_primary_10_3390_jcm11051335 crossref_primary_10_3390_life11040315 crossref_primary_10_1007_s00059_023_05205_2 crossref_primary_10_1016_j_jacc_2019_08_1017 crossref_primary_10_1055_a_2026_5196 crossref_primary_10_57187_smw_2023_40004 crossref_primary_10_1016_j_rccl_2020_10_017 crossref_primary_10_1016_j_kint_2021_04_029 crossref_primary_10_1016_j_ekir_2021_02_041 crossref_primary_10_3389_fcvm_2022_937474 crossref_primary_10_1097_MNH_0000000000000628 crossref_primary_10_34067_KID_0007022021 crossref_primary_10_1007_s11883_025_01290_2 crossref_primary_10_56095_eaj_v2i2_47 crossref_primary_10_1007_s00424_025_03069_5 crossref_primary_10_1007_s12170_025_00763_y crossref_primary_10_1016_j_nefro_2021_07_010 crossref_primary_10_1007_s11255_020_02547_2 crossref_primary_10_1016_j_biopha_2022_114170 crossref_primary_10_1097_MOL_0000000000000830 crossref_primary_10_1016_j_xkme_2021_04_008 crossref_primary_10_1007_s13730_021_00605_x crossref_primary_10_1007_s10557_020_07020_x crossref_primary_10_1016_j_semerg_2025_102460 crossref_primary_10_1152_ajprenal_00065_2024 crossref_primary_10_1016_j_ccl_2021_04_008 crossref_primary_10_1016_j_rccl_2024_06_002 crossref_primary_10_1080_14728222_2022_2161887 crossref_primary_10_1016_j_transproceed_2023_07_020 crossref_primary_10_3389_fphar_2024_1353848 crossref_primary_10_56095_eaj_v1i1_7 crossref_primary_10_1016_j_nefro_2022_04_006 crossref_primary_10_1186_s12920_024_02020_4 crossref_primary_10_3390_biomedicines11020291 crossref_primary_10_2478_jtim_2024_0014 crossref_primary_10_1093_ckj_sfaa001 crossref_primary_10_1016_S1131_3587_20_30025_X crossref_primary_10_1186_s12882_024_03664_1 crossref_primary_10_23876_j_krcp_22_237 crossref_primary_10_3390_jcm14020643 crossref_primary_10_1016_j_jcjd_2019_07_003 crossref_primary_10_1038_s41746_025_01557_7 crossref_primary_10_1159_000533970 crossref_primary_10_1016_j_atherosclerosis_2022_04_012 crossref_primary_10_3390_antiox12122083 crossref_primary_10_36290_med_2020_029 crossref_primary_10_15829_1728_8800_2024_3996 crossref_primary_10_3390_pharmaceutics15010006 crossref_primary_10_1159_000518456 crossref_primary_10_5604_01_3001_0015_4805 crossref_primary_10_1093_ckj_sfab288 crossref_primary_10_1038_s41581_023_00741_w crossref_primary_10_1093_ckj_sfae421 crossref_primary_10_1016_j_atherosclerosis_2022_04_007 crossref_primary_10_1177_10600280231165774 crossref_primary_10_1016_j_pharmthera_2023_108480 crossref_primary_10_3389_fcvm_2022_859567 crossref_primary_10_55783_AMF_191102 crossref_primary_10_3390_jcm13175040 crossref_primary_10_1016_j_nefro_2020_04_020 crossref_primary_10_1093_eurheartj_ehac531 crossref_primary_10_1097_HJH_0000000000002506 crossref_primary_10_1093_eurheartj_ehad192 crossref_primary_10_1097_FJC_0000000000000809 crossref_primary_10_1007_s11886_021_01453_y crossref_primary_10_1016_j_jacc_2019_03_514 crossref_primary_10_1016_S2213_8587_19_30389_4 crossref_primary_10_1097_TP_0000000000004942 crossref_primary_10_1007_s10557_020_07017_6 crossref_primary_10_1016_j_jacc_2024_06_041 crossref_primary_10_1093_cvr_cvad083 crossref_primary_10_1097_IMNA_D_22_00023 crossref_primary_10_3390_metabo11110760 crossref_primary_10_1016_j_nefroe_2020_11_004 crossref_primary_10_1007_s00108_019_00686_y crossref_primary_10_1007_s40620_021_01086_y crossref_primary_10_1016_j_nefroe_2024_02_007 crossref_primary_10_1097_MED_0000000000000594 crossref_primary_10_1161_JAHA_120_018897 crossref_primary_10_1038_s41581_021_00423_5 crossref_primary_10_1093_eurjpc_zwab154 crossref_primary_10_1016_j_kint_2023_10_018 crossref_primary_10_1007_s11560_020_00421_x crossref_primary_10_1093_eurheartj_ehaa498 crossref_primary_10_1371_journal_pone_0302547 crossref_primary_10_15829_1728_8800_2022_3235 crossref_primary_10_15829_1560_4071_2022_5271 crossref_primary_10_1161_CIRCRESAHA_122_321748 crossref_primary_10_1080_14740338_2020_1732921 crossref_primary_10_1007_s40620_020_00707_2 crossref_primary_10_1007_s11892_019_1246_y crossref_primary_10_1007_s11560_023_00686_y crossref_primary_10_1186_s12933_023_01927_z crossref_primary_10_1016_j_jfma_2024_09_037 crossref_primary_10_1016_j_kint_2023_06_024 crossref_primary_10_3389_fcvm_2021_789931 crossref_primary_10_1186_s12933_021_01247_0 |
| Cites_doi | 10.1056/NEJMoa043545 10.1097/01.ASN.0000135969.33773.0B 10.1053/j.ajkd.2005.11.017 10.1056/NEJMoa1501031 10.1016/S0140-6736(17)32290-0 10.1056/NEJMoa041365 10.1056/NEJMoa041031 10.1056/NEJMoa0810177 10.1681/ASN.2016090957 10.1056/NEJMoa1615664 10.7326/0003-4819-139-2-200307150-00013 10.1161/01.CIR.0000143892.84582.60 10.1681/ASN.2013090965 10.1016/S0140-6736(11)60739-3 10.2215/CJN.09320913 10.1056/NEJMoa1801174 10.1016/j.kint.2017.12.011 10.7326/0003-4819-150-9-200905050-00006 10.1001/jama.286.12.1494 10.1016/S2213-8587(16)30156-5 10.1056/NEJMoa1500858 10.1016/j.atherosclerosis.2008.11.010 10.1016/j.ahj.2015.11.015 |
| ContentType | Journal Article |
| Copyright | 2019 American College of Cardiology Foundation American College of Cardiology Foundation Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. 2019. American College of Cardiology Foundation |
| Copyright_xml | – notice: 2019 American College of Cardiology Foundation – notice: American College of Cardiology Foundation – notice: Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. – notice: 2019. American College of Cardiology Foundation |
| CorporateAuthor | FOURIER Steering Committee and Investigators |
| CorporateAuthor_xml | – name: FOURIER Steering Committee and Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK H94 K9. NAPCQ 7X8 ADTPV AOWAS DG8 ADTOC UNPAY |
| DOI | 10.1016/j.jacc.2019.03.513 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic SwePub SwePub Articles SWEPUB Linköpings universitet Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1558-3597 |
| EndPage | 2970 |
| ExternalDocumentID | oai:spiral.imperial.ac.uk:10044/1/75008 oai_DiVA_org_liu_158544 31196453 10_1016_j_jacc_2019_03_513 1_s2_0_S0735109719349034 S0735109719349034 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 18M 1B1 1P~ 1~. 1~5 2WC 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ AABNK AABVL AAEDT AAEDW AAIKJ AALRI AAOAW AAQFI AAQQT AAXUO ABBQC ABFNM ABFRF ABLJU ABMAC ABMZM ABOCM ACGFO ACGFS ACIUM ACJTP ACPRK ACVFH ADBBV ADCNI ADEZE ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFPUW AFRAH AFRHN AFTJW AGYEJ AHMBA AIGII AITUG AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CS3 DIK DU5 E3Z EBS EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FNPLU G-Q GBLVA GX1 HVGLF IHE IXB J1W K-O KQ8 L7B MO0 N9A O-L O9- OA. OAUVE OK1 OL~ OZT P-8 P-9 P2P PC. PQQKQ Q38 ROL RPZ SCC SDF SDG SDP SES SSZ TR2 UNMZH UV1 W8F WH7 WOQ WOW YYM YZZ Z5R ~HD .55 .GJ 0SF 1CY 29L 3O- 3V. 6I. 7RV AACTN AAFTH AAKUH AAQXK AAYOK ABVKL ABWVN ABXDB ACRPL ADMUD ADNMO AFCTW AFETI AFFNX AGHFR AJOXV AMFUW ASPBG AVWKF AZFZN BENPR BPHCQ FGOYB H13 HX~ HZ~ J5H N4W NCXOZ PROAC QTD R2- RIG SEW T5K X7M XPP YYP ZGI ZXP AAYWO AAYXX AGQPQ CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK H94 K9. NAPCQ 7X8 ADTPV AGCQF AOWAS DG8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c585t-bf14f2016042feeafa999156520d5202943e88959b2ff5db60209fa09255d1123 |
| IEDL.DBID | UNPAY |
| ISSN | 0735-1097 1558-3597 |
| IngestDate | Sun Oct 26 03:28:59 EDT 2025 Tue Sep 09 22:25:36 EDT 2025 Thu Oct 02 19:13:26 EDT 2025 Tue Oct 07 07:35:55 EDT 2025 Wed Feb 19 02:30:13 EST 2025 Thu Apr 24 23:10:39 EDT 2025 Wed Oct 01 02:08:25 EDT 2025 Sun Feb 23 10:18:58 EST 2025 Tue Oct 14 19:28:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 23 |
| Keywords | atherosclerosis eGFR cardiovascular disease ARR chronic kidney disease lipids LDL-C NNT PCSK9 HR cardiovascular risk CKD estimated glomerular filtration rate low-density lipoprotein cholesterol absolute risk reduction hazard ratio proprotein convertase subtilisin–kexin type 9 number needed to treat |
| Language | English |
| License | This article is made available under the Elsevier license. Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. cc-by-nc-nd |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c585t-bf14f2016042feeafa999156520d5202943e88959b2ff5db60209fa09255d1123 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=http://hdl.handle.net/10044/1/75008 |
| PMID | 31196453 |
| PQID | 2237810994 |
| PQPubID | 2031078 |
| PageCount | 10 |
| ParticipantIDs | unpaywall_primary_10_1016_j_jacc_2019_03_513 swepub_primary_oai_DiVA_org_liu_158544 proquest_miscellaneous_2340043994 proquest_journals_2237810994 pubmed_primary_31196453 crossref_citationtrail_10_1016_j_jacc_2019_03_513 crossref_primary_10_1016_j_jacc_2019_03_513 elsevier_clinicalkeyesjournals_1_s2_0_S0735109719349034 elsevier_clinicalkey_doi_10_1016_j_jacc_2019_03_513 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-06-18 |
| PublicationDateYYYYMMDD | 2019-06-18 |
| PublicationDate_xml | – month: 06 year: 2019 text: 2019-06-18 day: 18 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: New York |
| PublicationTitle | Journal of the American College of Cardiology |
| PublicationTitleAlternate | J Am Coll Cardiol |
| PublicationYear | 2019 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Levey, Stevens, Schmid (bib12) 2009; 150 Sabatine, Giugliano, Keech (bib11) 2016; 173 Sosnov, Lessard, Goldberg, Yarzebski, Gore (bib20) 2006; 47 Baigent, Landray, Reith (bib4) 2011; 377 Herrington, Emberson, Mihaylova (bib17) 2016; 4 Levey, Coresh, Balk (bib13) 2003; 139 Ghali, Quan, Brant (bib15) 2001; 286 Sabatine, Giugliano, Keech (bib7) 2017; 376 Sabatine, Giugliano, Wiviott (bib8) 2015; 372 Anavekar, McMurray, Velazquez (bib2) 2004; 351 Tonelli, Isles, Curhan (bib16) 2004; 110 Go, Chertow, Fan, McCulloch, Hsu (bib1) 2004; 351 Wanner, Krane, Marz (bib3) 2005; 353 Huskey, Lindenfeld, Cook (bib21) 2009; 205 Robinson, Farnier, Krempf (bib9) 2015; 372 Toth, Dwyer, Cannon (bib18) 2018; 93 Chertow, Normand, McNeil (bib19) 2004; 15 Schwartz, Steg, Szarek (bib10) 2018; 379 Fellstrom, Jardine, Schmieder (bib5) 2009; 360 Stanifer, Charytan, White (bib6) 2017; 28 Giugliano, Pedersen, Park (bib14) 2017; 390 Rahman, Yang, Akkina (bib22) 2014; 9 Haynes, Lewis, Emberson (bib23) 2014; 25 Haynes (10.1016/j.jacc.2019.03.513_bib23) 2014; 25 Go (10.1016/j.jacc.2019.03.513_bib1) 2004; 351 Levey (10.1016/j.jacc.2019.03.513_bib12) 2009; 150 Anavekar (10.1016/j.jacc.2019.03.513_bib2) 2004; 351 Ghali (10.1016/j.jacc.2019.03.513_bib15) 2001; 286 Sabatine (10.1016/j.jacc.2019.03.513_bib7) 2017; 376 Tonelli (10.1016/j.jacc.2019.03.513_bib16) 2004; 110 Robinson (10.1016/j.jacc.2019.03.513_bib9) 2015; 372 Herrington (10.1016/j.jacc.2019.03.513_bib17) 2016; 4 Fellstrom (10.1016/j.jacc.2019.03.513_bib5) 2009; 360 Giugliano (10.1016/j.jacc.2019.03.513_bib14) 2017; 390 Wanner (10.1016/j.jacc.2019.03.513_bib3) 2005; 353 Stanifer (10.1016/j.jacc.2019.03.513_bib6) 2017; 28 Sabatine (10.1016/j.jacc.2019.03.513_bib8) 2015; 372 Chertow (10.1016/j.jacc.2019.03.513_bib19) 2004; 15 Levey (10.1016/j.jacc.2019.03.513_bib13) 2003; 139 Sosnov (10.1016/j.jacc.2019.03.513_bib20) 2006; 47 Baigent (10.1016/j.jacc.2019.03.513_bib4) 2011; 377 Sabatine (10.1016/j.jacc.2019.03.513_bib11) 2016; 173 Schwartz (10.1016/j.jacc.2019.03.513_bib10) 2018; 379 Rahman (10.1016/j.jacc.2019.03.513_bib22) 2014; 9 Huskey (10.1016/j.jacc.2019.03.513_bib21) 2009; 205 Toth (10.1016/j.jacc.2019.03.513_bib18) 2018; 93 31196454 - J Am Coll Cardiol. 2019 Jun 18;73(23):2971-2975 31439225 - J Am Coll Cardiol. 2019 Aug 27;74(8):1162-1166 |
| References_xml | – volume: 379 start-page: 2097 year: 2018 end-page: 2107 ident: bib10 article-title: Alirocumab and cardiovascular outcomes after acute coronary syndrome publication-title: N Engl J Med – volume: 173 start-page: 94 year: 2016 end-page: 101 ident: bib11 article-title: Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial publication-title: Am Heart J – volume: 47 start-page: 378 year: 2006 end-page: 384 ident: bib20 article-title: Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective publication-title: Am J Kidney Dis – volume: 9 start-page: 1190 year: 2014 end-page: 1198 ident: bib22 article-title: Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study publication-title: Clin J Am Soc Nephrol – volume: 376 start-page: 1713 year: 2017 end-page: 1722 ident: bib7 article-title: Evolocumab and clinical outcomes in patients with cardiovascular disease publication-title: N Engl J Med – volume: 25 start-page: 1825 year: 2014 end-page: 1833 ident: bib23 article-title: Effects of lowering LDL cholesterol on progression of kidney disease publication-title: J Am Soc Nephrol – volume: 377 start-page: 2181 year: 2011 end-page: 2192 ident: bib4 article-title: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial publication-title: Lancet – volume: 28 start-page: 3034 year: 2017 end-page: 3043 ident: bib6 article-title: Benefit of ezetimibe added to simvastatin in reduced kidney function publication-title: J Am Soc Nephrol – volume: 372 start-page: 1500 year: 2015 end-page: 1509 ident: bib8 article-title: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events publication-title: N Engl J Med – volume: 4 start-page: 829 year: 2016 end-page: 839 ident: bib17 article-title: Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials publication-title: Lancet Diabetes Endocrinol – volume: 205 start-page: 202 year: 2009 end-page: 206 ident: bib21 article-title: Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S) publication-title: Atherosclerosis – volume: 390 start-page: 1962 year: 2017 end-page: 1971 ident: bib14 article-title: Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial publication-title: Lancet – volume: 139 start-page: 137 year: 2003 end-page: 147 ident: bib13 article-title: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification publication-title: Ann Intern Med – volume: 286 start-page: 1494 year: 2001 end-page: 1497 ident: bib15 article-title: Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models publication-title: JAMA – volume: 360 start-page: 1395 year: 2009 end-page: 1407 ident: bib5 article-title: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis publication-title: N Engl J Med – volume: 372 start-page: 1489 year: 2015 end-page: 1499 ident: bib9 article-title: Efficacy and safety of alirocumab in reducing lipids and cardiovascular events publication-title: N Engl J Med – volume: 15 start-page: 2462 year: 2004 end-page: 2468 ident: bib19 article-title: “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency publication-title: J Am Soc Nephrol – volume: 351 start-page: 1285 year: 2004 end-page: 1295 ident: bib2 article-title: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction publication-title: N Engl J Med – volume: 353 start-page: 238 year: 2005 end-page: 248 ident: bib3 article-title: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis publication-title: N Engl J Med – volume: 110 start-page: 1557 year: 2004 end-page: 1563 ident: bib16 article-title: Effect of pravastatin on cardiovascular events in people with chronic kidney disease publication-title: Circulation – volume: 351 start-page: 1296 year: 2004 end-page: 1305 ident: bib1 article-title: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization publication-title: N Engl J Med – volume: 150 start-page: 604 year: 2009 end-page: 612 ident: bib12 article-title: A new equation to estimate glomerular filtration rate publication-title: Ann Intern Med – volume: 93 start-page: 1397 year: 2018 end-page: 1408 ident: bib18 article-title: Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease publication-title: Kidney Int – volume: 353 start-page: 238 year: 2005 ident: 10.1016/j.jacc.2019.03.513_bib3 article-title: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis publication-title: N Engl J Med doi: 10.1056/NEJMoa043545 – volume: 15 start-page: 2462 year: 2004 ident: 10.1016/j.jacc.2019.03.513_bib19 article-title: “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000135969.33773.0B – volume: 47 start-page: 378 year: 2006 ident: 10.1016/j.jacc.2019.03.513_bib20 article-title: Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2005.11.017 – volume: 372 start-page: 1489 year: 2015 ident: 10.1016/j.jacc.2019.03.513_bib9 article-title: Efficacy and safety of alirocumab in reducing lipids and cardiovascular events publication-title: N Engl J Med doi: 10.1056/NEJMoa1501031 – volume: 390 start-page: 1962 year: 2017 ident: 10.1016/j.jacc.2019.03.513_bib14 article-title: Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial publication-title: Lancet doi: 10.1016/S0140-6736(17)32290-0 – volume: 351 start-page: 1285 year: 2004 ident: 10.1016/j.jacc.2019.03.513_bib2 article-title: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction publication-title: N Engl J Med doi: 10.1056/NEJMoa041365 – volume: 351 start-page: 1296 year: 2004 ident: 10.1016/j.jacc.2019.03.513_bib1 article-title: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization publication-title: N Engl J Med doi: 10.1056/NEJMoa041031 – volume: 360 start-page: 1395 year: 2009 ident: 10.1016/j.jacc.2019.03.513_bib5 article-title: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis publication-title: N Engl J Med doi: 10.1056/NEJMoa0810177 – volume: 28 start-page: 3034 year: 2017 ident: 10.1016/j.jacc.2019.03.513_bib6 article-title: Benefit of ezetimibe added to simvastatin in reduced kidney function publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2016090957 – volume: 376 start-page: 1713 year: 2017 ident: 10.1016/j.jacc.2019.03.513_bib7 article-title: Evolocumab and clinical outcomes in patients with cardiovascular disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1615664 – volume: 139 start-page: 137 year: 2003 ident: 10.1016/j.jacc.2019.03.513_bib13 article-title: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification publication-title: Ann Intern Med doi: 10.7326/0003-4819-139-2-200307150-00013 – volume: 110 start-page: 1557 year: 2004 ident: 10.1016/j.jacc.2019.03.513_bib16 article-title: Effect of pravastatin on cardiovascular events in people with chronic kidney disease publication-title: Circulation doi: 10.1161/01.CIR.0000143892.84582.60 – volume: 25 start-page: 1825 year: 2014 ident: 10.1016/j.jacc.2019.03.513_bib23 article-title: Effects of lowering LDL cholesterol on progression of kidney disease publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2013090965 – volume: 377 start-page: 2181 year: 2011 ident: 10.1016/j.jacc.2019.03.513_bib4 article-title: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(11)60739-3 – volume: 9 start-page: 1190 year: 2014 ident: 10.1016/j.jacc.2019.03.513_bib22 article-title: Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.09320913 – volume: 379 start-page: 2097 year: 2018 ident: 10.1016/j.jacc.2019.03.513_bib10 article-title: Alirocumab and cardiovascular outcomes after acute coronary syndrome publication-title: N Engl J Med doi: 10.1056/NEJMoa1801174 – volume: 93 start-page: 1397 year: 2018 ident: 10.1016/j.jacc.2019.03.513_bib18 article-title: Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease publication-title: Kidney Int doi: 10.1016/j.kint.2017.12.011 – volume: 150 start-page: 604 year: 2009 ident: 10.1016/j.jacc.2019.03.513_bib12 article-title: A new equation to estimate glomerular filtration rate publication-title: Ann Intern Med doi: 10.7326/0003-4819-150-9-200905050-00006 – volume: 286 start-page: 1494 year: 2001 ident: 10.1016/j.jacc.2019.03.513_bib15 article-title: Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models publication-title: JAMA doi: 10.1001/jama.286.12.1494 – volume: 4 start-page: 829 year: 2016 ident: 10.1016/j.jacc.2019.03.513_bib17 article-title: Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(16)30156-5 – volume: 372 start-page: 1500 year: 2015 ident: 10.1016/j.jacc.2019.03.513_bib8 article-title: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events publication-title: N Engl J Med doi: 10.1056/NEJMoa1500858 – volume: 205 start-page: 202 year: 2009 ident: 10.1016/j.jacc.2019.03.513_bib21 article-title: Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S) publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2008.11.010 – volume: 173 start-page: 94 year: 2016 ident: 10.1016/j.jacc.2019.03.513_bib11 article-title: Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial publication-title: Am Heart J doi: 10.1016/j.ahj.2015.11.015 – reference: 31439225 - J Am Coll Cardiol. 2019 Aug 27;74(8):1162-1166 – reference: 31196454 - J Am Coll Cardiol. 2019 Jun 18;73(23):2971-2975 |
| SSID | ssj0006819 |
| Score | 2.6247833 |
| Snippet | Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited.
The purpose of this study was to compare outcomes with evolocumab and placebo according to... AbstractBackgroundData on PCSK9 inhibition in chronic kidney disease (CKD) is limited. ObjectivesThe purpose of this study was to compare outcomes with... BackgroundData on PCSK9 inhibition in chronic kidney disease (CKD) is limited.ObjectivesThe purpose of this study was to compare outcomes with evolocumab and... Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited.BACKGROUNDData on PCSK9 inhibition in chronic kidney disease (CKD) is limited.The purpose... BACK GROUND Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. OBJECTIVES The purpose of this study was to compare outcomes with evolocumab... |
| SourceID | unpaywall swepub proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2961 |
| SubjectTerms | Adult Aged Aged, 80 and over Angina Angina pectoris Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Arteriosclerosis atherosclerosis Atherosclerosis - blood Atherosclerosis - drug therapy Atherosclerosis - epidemiology Cardiology Cardiovascular Cardiovascular disease Cardiovascular Diseases - blood Cardiovascular Diseases - drug therapy Cardiovascular Diseases - epidemiology cardiovascular risk Cerebral infarction Cholesterol Cholesterol, LDL - blood chronic kidney disease Death Diabetes Double-Blind Method Epidemiology Female Follow-Up Studies Glomerular filtration rate Heart attacks Humans Kidney diseases Laboratories lipids Low density lipoprotein Male Middle Aged Monoclonal antibodies Myocardial infarction PCSK9 Proprotein Convertase 9 - antagonists & inhibitors Proprotein Convertase 9 - blood Renal Insufficiency, Chronic - blood Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - epidemiology Safety Statins Stroke Treatment Outcome |
| Title | Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0735109719349034 https://www.clinicalkey.es/playcontent/1-s2.0-S0735109719349034 https://www.ncbi.nlm.nih.gov/pubmed/31196453 https://www.proquest.com/docview/2237810994 https://www.proquest.com/docview/2340043994 https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-158544 http://hdl.handle.net/10044/1/75008 |
| UnpaywallVersion | submittedVersion |
| Volume | 73 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1558-3597 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006819 issn: 0735-1097 databaseCode: KQ8 dateStart: 19980101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1558-3597 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006819 issn: 0735-1097 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Science Direct customDbUrl: eissn: 1558-3597 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006819 issn: 0735-1097 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Open Access Journals (Elsevier) customDbUrl: eissn: 1558-3597 dateEnd: 20241028 omitProxy: true ssIdentifier: ssj0006819 issn: 0735-1097 databaseCode: IXB dateStart: 19830101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1558-3597 dateEnd: 20241028 omitProxy: true ssIdentifier: ssj0006819 issn: 0735-1097 databaseCode: DIK dateStart: 19830101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1558-3597 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006819 issn: 0735-1097 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1558-3597 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006819 issn: 0735-1097 databaseCode: AKRWK dateStart: 19830101 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELbKVuJx4P1YKJWREBfINo7z8nHF7qqAWtC2i8rJshO72nZJqm4itBz4Lf0t_WXM5CVEYQWHHCKPrTgzY3_WeL4h5KXgrlJhZB04e2jHT5PIUV5oHcZ9q10l3LQKxezth7sz__1RcLRB2oJ3v9ELVHRmO2wHtjVM6N0MAwDcPbI52_80_FIRbHLk0axLqARB7HDAx01qTH2L60QlSFTIKirTgPG_bT9X4WXHHXqL3CizM7X6phaLX_aeyR0yajN46isnp4Oy0IPk-1VCx3XTuktuN9iTDmtjuUc2THafXN9rousPyHSMfBIqWVEYhB4oa4oVzS0dwxKWJ-VXpek8u7xo-HTph3mamRUd1SEeaKIAJunk42z6bjy9vDhE035IZpPx4dtdp6m54CRwcCgcbZlvPaSd8z1rjLIKESSgPs9N4fGEz00ci0Boz9og1SHATWGVK-BokgJ2449IL8sz84TQ0CQeeLhrkEE-ClMRidRjKoRRUh0z0yesVYVMGkJyrIuxkO3NsxOJ6pOoPulyCerrk9ddn7OajmOtNG81LNtEU1gaJewWa3tFf-pllo13LyWTS0-68gDND60PQLAvXO73yVZrRrITBvwVxRh_hOYXXTM4MUZmVGbyEmQ4LqW8knlcm183Pc6QMy2Az3pV22PXgszgo_nnoczPj-ViXkoGKvRhiDedvf7DT3r6f-LPyE18w9tyLN4iveK8NM8BlxV6m1wb_GDbjXf-BDTBL2M |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaqrQT0UJ6FLQUZCXGBtHGcl48rdlcF1IK2XVROlp3YaNslqbqJqu2v6W_pL2MmLyEKKzjkEHlsxZkZ-7PG8w0hrwV3lQoj68DZQzt-mkSO8kLrMO5b7SrhplUo5uAw3J_6H0-CkzXSFrz7jV6gojPbY3uwrWFC73oYAODukfXp4ZfBt4pgkyOPZl1CJQhihwM-blJj6ltcpypBokJWUZkGjP9t-7kNLzvu0A1yt8zO1fJSzee_7D3j-2TYZvDUV07OdstC7yZXtwkdV03rAdlssCcd1MbykKyZ7BG5c9BE1x-TyQj5JFSypDAIPVLWFEuaWzqCJSxPyh9K01l2c93w6dJPszQzSzqsQzzQRAFM0vHn6eTDaHJzfYym_YRMx6Pj9_tOU3PBSeDgUDjaMt96SDvne9YYZRUiSEB9npvC4wmfmzgWgdCetUGqQ4CbwipXwNEkBezGt0gvyzPzjNDQJB54uGuQQT4KUxGJ1GMqhFFSHTPTJ6xVhUwaQnKsizGX7c2zU4nqk6g-6XIJ6uuTt12f85qOY6U0bzUs20RTWBol7BYre0V_6mUWjXcvJJMLT7ryCM0PrQ9AsC9c7vfJTmtGshMG_BXFGH-E5lddMzgxRmZUZvISZDgupbySeVqbXzc9zpAzLYDPelPbY9eCzODD2deBzC--y_mslAxU6MMQ7zp7_YeftP1_4s_JPXzD23Is3iG94qI0LwCXFfpl45c_AR4NLmU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+Safety+of+Evolocumab+in%C2%A0Chronic+Kidney+Disease+in+the+FOURIER%C2%A0Trial&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Charytan%2C+David+M.&rft.au=Sabatine%2C+Marc+S.&rft.au=Pedersen%2C+Terje+R.&rft.au=Im%2C+KyungAh&rft.date=2019-06-18&rft.issn=0735-1097&rft.volume=73&rft.issue=23&rft.spage=2961&rft.epage=2970&rft_id=info:doi/10.1016%2Fj.jacc.2019.03.513&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jacc_2019_03_513 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F07351097%2FS0735109718X00291%2Fcov150h.gif |